Articles By Wayne Koberstein, Executive Editor

Novabiotics_Deb O'Neil_450x300.jpg
COVID Revs Up The Antibiotics Space
NovaBiotics’ CEO, Deborah O’Neil, shares some surprising information about the way Covid has enlivened not only her company’s area of business, but also the antibiotics space industrywide.  Continue Reading..
  • Women In Bio: Riding The Waves Of Change

    WIB’s top execs discuss how the group is faring in the midst of two world-transforming events: the Covid-19 pandemic and the Black Lives Matter protest.

  • Companies To Watch: Osivax

    Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.

  • Companies To Watch: CalciMedica

    “In a sense, the Covid association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for Covid-19 pneumonia.

  • Eyes On Horizon, Buying Into Bio

    CEO Tim Walbert talks about how his company, Horizon Therapeutics, has gone from acquiring commercial drugs and remarketing them to using their R&D to focus more on bio-based medicines such as monoclonal antibodies and genetically engineered proteins.

  • The Co-Opportunities Of COVID-19

    An interview with Arda Ural, Ph.D., who leads the life sciences team at Ernst & Young, which is tracking biopharma’s readiness and reaction to the COVID-19 pandemic.

  • Companies To Watch: Cidara Therapeutics

    Cidara Therapeutics is training its novel treatment and preventative for flu and other viral infections on Covid-19.

  • Companies To Watch: Equillium

    Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.

  • The Viral Startup

    ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.

  • Companies To Watch: Spring Bank Pharmaceuticals

    Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.

  • A European Model For Innovative Bio Funding

    Challenge breeds creativity, and a fresh example of that has emerged in Germany’s Ruhr Valley, with the company Abalos Therapeutics and the unique funding model that supported its launch.

  • Companies To Watch: argenx

    Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.

  • Companies To Watch: Neurana

    This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.

  • Making Progress On A Micro-Budget

    Started in 2017, Eikonizo Therapeutics has led an uphill battle to getting funding for its pipeline that includes drugs for ALS and Alzheimer’s, among other neurodegenerative diseases.

  • A New Life In Bio

    This unlikely CEO’s experience offers some valuable lessons in founding and scaling up a biotech company, particularly one in a nascent space such as regenerative medicine.

wayne koberstein

Wayne Koberstein

Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.